logo

For the Inventor, By the Inventor

Branford, CT, United States of America

Neurogen Corporation

Calculating rank
USPTO Granted Patents = 305

% Expired Patents = 31.5



Forward Citations = 2,355

Loading Chart...
Loading Chart...

121 inventors (with patents filed for the assignee):

goldMedal Alan J Hutchison (103 out of 128 patents)

silverMedal Jun Yuan (86 out of 110 patents)

bronzeMedal Andrew Y Thurkauf (63 out of 77 patents)

4.  Pamela Ann Albaugh (53 out of 65 patents)

5.  Kenneth Shaw (38 out of 52 patents)

6.  George D Maynard (36 out of 65 patents)

7.  Xi Chen (29 out of 34 patents)

8.  Raymond F Horvath (28 out of 30 patents)

9.  Charles A Blum (28 out of 39 patents)

10.  John M Peterson (25 out of 26 patents)

11.  Robert W DeSimone (25 out of 34 patents)

12.  Xiao-shu He (20 out of 20 patents)

13.  Guolin Cai (19 out of 30 patents)

14.  Taeyoung Yoon (18 out of 22 patents)

15.  Gang Liu (17 out of 66 patents)


Core Competencies:
C5a Receptor Modulators
GABA Receptor Ligands
Melanin Concentrating Hormone
Pyrimidine Derivatives
Piperazine Analogues
Quinazolin-4-ylamine
Imidazole Derivatives
Biaryl Compounds
Dopamine Receptor Ligands
Heterocyclic Compounds
Neurokinin Receptor Ligands
Capsaicin Receptor Ligands

305 patents:

1. 8759361 - 2-phenoxy pyrimidinone analogues (2014-06-24),
2. 8334382 - Substituted biaryl piperazinyl-pyridine analogues (2012-12-18),
3. 8003656 - 2-phenoxy pyrimidinone analogues (2011-08-23),
4. 7935702 - Substituted biaryl quinolin-4-ylamine analogues (2011-05-03),
5. 7851474 - Dipiperazinyl ketones and related analogues (2010-12-14),
6. 7795262 - Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues (2010-09-14),
7. 7728009 - Thiazole amides, imidazole amides and related analogues (2010-06-01),
8. 7662830 - Substituted biaryl piperazinyl-pyridine analogues (2010-02-16),
9. 7642267 - Benzimidazole and pyridylimidazole derivatives (2010-01-05),
10. 7566712 - Biaryl piperazinyl-pyridine analogues (2009-07-28),
11. 7488740 - Substituted quinolin-4-ylamine analogues (2009-02-10),
12. 7482350 - 4,5-disubstituted-2-aryl pyrimidines (2009-01-27),
13. 7432275 - Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators (2008-10-07),
14. 7371752 - Aryl fused substituted 4-oxy-pyridines (2008-05-13),
15. 7351826 - Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds (2008-04-01),
Company Overview
Neurogen Corporation, based in Branford, Connecticut, specializes in the development of innovative pharmaceutical compounds targeting various neurological and psychiatric disorders. The company focuses on advanced research in areas such as C5a receptor modulators and GABA receptor ligands, contributing to the understanding and treatment of complex conditions. Their expertise extends to the synthesis of diverse chemical entities, including pyrimidine derivatives and biaryl compounds, positioning them at the forefront of pharmaceutical innovation.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Neurogen Corporation USPTO Patent Assignee Logo
305 Patents

#1 in Branford, CT

#42 in Connecticut

#1,440 in US

#2,931 in the World

Branford, CT (US)
Branford, CT, United States of America

Neurogen Corporation

Forward Citations = 2,355

121 inventors:

goldMedal Alan J Hutchison (103 out of 128 patents)

silverMedal Jun Yuan (86 out of 110 patents)

bronzeMedal Andrew Y Thurkauf (63 out of 77 patents)

4.  Pamela Ann Albaugh (53 out of 65 patents)

5.  Kenneth Shaw (38 out of 52 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neurogen Corporation. Retrieved from https://idiyas.com/company/neurogen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…